Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures
Addictive Behaviors | HIV/AIDS | Infectious Diseases
What is the purpose of this trial?
The purpose of this study is to understand changes in how your blood cells, genes, metabolism, and immune system work after you begin medication assisted therapy (MAT) (e.g. buprenorphine/naloxone, buprenorphine, methadone or extended-release naltrexone), for treatment of an opioid use disorder. The researchers will follow all participants and schedule regular interviews and blood draws to gather information. This will enable them to look at the presence of specific factors associated with treatment for opioid use disorder in those living with HIV infection and those without HIV infection. The study will last for 6 months.
- Ages18 years and older
- Trial withNational Institute on Drug Abuse (NIDA)
- Start Date03/31/2017
- End Date08/31/2021
- Last Updated02/05/2019
- Study HIC#1608018239